With the increased focus on beyond the first year of diagnosis in the anti-CD38 monoclonal antibody era, it is essential to perform Holter monitoring in patients with AL amyloidosis to identify and intervene with high-risk patients. The gene discussed is CD38; the disease is AL amyloidosis.